Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,869 | 13,274 | 30,134 | -15,311 | -5,197 |
| Depreciation Amortization | 763 | 2,993 | 2,267 | 1,525 | 759 |
| Accounts payable and accrued liabilities | 114 | 1,483 | 1,158 | 822 | 684 |
| Other Working Capital | -2,061 | -3,685 | 3,631 | 2,007 | 1,065 |
| Other Operating Activity | 5,782 | -58,839 | -65,189 | -3,992 | -5,108 |
| Operating Cash Flow | $-14,271 | $-44,775 | $-27,999 | $-14,949 | $-7,797 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -981 | -933 | 1 | 1 | 1 |
| Purchase Of Investment | -139,263 | -142,036 | -129,992 | -123 | -71 |
| Sale Of Investment | 74,596 | 21,262 | 9,991 | 9,991 | 4,742 |
| Investing Cash Flow | $-65,648 | $-121,706 | $-120,000 | $9,869 | $4,671 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -37 | -143 | -106 | -70 | -35 |
| Common Stock Issued | 3,088 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 86,870 | 168,442 | 168,447 | -278 | -139 |
| Financing Cash Flow | $89,921 | $168,300 | $168,341 | $-348 | $-174 |
| Exchange Rate Effect | 15 | -214 | 184 | 222 | 43 |
| Beginning Cash Position | 10,503 | 8,898 | 8,898 | 8,898 | 8,898 |
| End Cash Position | 20,520 | 10,503 | 29,425 | 3,692 | 5,640 |
| Net Cash Flow | $10,017 | $1,605 | $20,527 | $-5,206 | $-3,258 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,271 | -44,775 | -27,999 | -14,949 | -7,797 |
| Capital Expenditure | -983 | -933 | N/A | N/A | N/A |
| Free Cash Flow | -15,254 | -45,708 | -27,999 | -14,949 | -7,797 |